{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.2895","upperLimit":"1.0000","value":"0.6667"},{"groupId":"OG001","lowerLimit":"0.4303","upperLimit":"0.7070","value":"0.5686"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"51"}],"units":"Participants"}],"description":"4-year EFS (probability of no relapse, secondary malignancy, or death after 4 years in the study)","dispersionType":"95% Confidence Interval","groups":[{"id":"OG000","title":"% Change in SUVmax From Baseline to Week 15 < 40%"},{"id":"OG001","title":"% Change in SUVmax From Baseline to Week 15 >= 40%"}],"paramType":"NUMBER","populationDescription":"421 participants were excluded due to ineligibility or absence of SUVmax evaluation at baseline and week 15.","reportingStatus":"POSTED","timeFrame":"4 years","title":"Compare Event Free Survival (EFS) With Respect to the Level of % Change in FDG PET Maximum Standard Uptake Value (SUVmax) at Week 15","type":"SECONDARY","unitOfMeasure":"Probability"}